Kerendia™ (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes

Berlin, February 10, 2023 – The European Commission granted approval for a label extension for Kerendia™ (finerenone) in the European Union (EU) to include results on cardiovascular (CV) outcomes from the Phase III FIGARO-DKD study. The study demonstrated that Kerendia reduced the risk of CV events in a broad population of patients with stages 1-4 CKD and T2D…
Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

This website is using cookies to improve the user-friendliness. You agree by using the website further.

Privacy policy
Skip to content